VYNE Therapeutics 2024年第四季度GAAP每股收益$(0.28) 超预期$(0.30),销售额$84,000K 未达$140,000K预期

财报速递
06 Mar
VYNE Therapeutics(LENZ) 2024年第四季度GAAP每股收益$(0.28) 超预期$(0.30),销售额$84,000K 未达$140,000K预期。

以上内容来自Benzinga Earnings专栏,原文如下:

VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10